neurofibromatosis type 1
Showing 1 - 25 of >10,000
Mitochondrial Dysfunction in Neurofibromatosis Type 1
Not yet recruiting
- Neurofibromatosis 1
- Blood draw
- FACIT-F and Pain Scales
- (no location specified)
Jun 12, 2023
Neurofibromatosis 1 Trial in Boston (Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser)
Not yet recruiting
- Neurofibromatosis 1
- Deoxycholic Acid
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine
Nov 13, 2023
Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Completed
- Neurofibromatosis Type 1
- Neurofibroma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group
Not yet recruiting
- Neurofibromatosis 1
- +2 more
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Control group (Group B): Placebo, orally, once daily;
- (no location specified)
Jun 16, 2023
Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma, Plexiform
- Medication Event Monitoring System (MEMS)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
Development to Predict Malignant Conversion in Neurofibromatosis
Recruiting
- Neurofibromatosis 1
- +2 more
- Whole Body Magnetic Resonance Imaging
-
Baltimore, MarylandJohns Hopkins University
Dec 22, 2022
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Disfigurement From Photographs of Neurofibromatosis Type 1
Completed
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
-
Shanghai, China
- +1 more
Jan 13, 2023
Neurofibromatosis 1 Trial in Baltimore, Redwood City
Recruiting
- Neurofibromatosis 1
-
Baltimore, California
- +1 more
Aug 17, 2022
Neurofibromatosis Type 1 Trial in Los Angeles (Whole-body Magnetic Resonance Imaging)
Recruiting
- Neurofibromatosis Type 1
- Whole-body Magnetic Resonance Imaging
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Jul 11, 2022
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Cutaneous Neurofibroma Trial in Boston (Kybella, 980nm laser, 755nm Alexandrite Laser)
Recruiting
- Cutaneous Neurofibroma
- Kybella
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine, Massachusetts General Hospital
Aug 10, 2022
Cutaneous Neurofibromas in People With NF1
Recruiting
- Neurofibromatosis Type 1
- +3 more
- Evaluation of the natural history of cutaneous neurofibromas
-
Baltimore, MarylandJohns Hopkins University
Oct 12, 2022
Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)
Not yet recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
- Placebo
-
Beijing, China
- +2 more
Apr 11, 2023
Stressors in Parents of Cancer or Neurofibromatosis Type 1 (NF1)
Completed
- Parents of Children With Cancer
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Neurofibromatosis, MPNST Trial run by the National Cancer Institute (NCI) (MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans)
Completed
- Neurofibromatosis
- MPNST
- MRI, FDG-PET/CT scans
- [18F]-FLT-PET/CT scans
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
-
Rochester, Minnesota
- +8 more
Nov 10, 2022
Frameshift Peptides of Children With NF1
Completed
- Neurofibromatosis Type 1
- Frameshift Array blood sample test
-
Washington, District of Columbia
- +2 more
Aug 29, 2022
Cutaneous Neurofibroma Trial in Copenhagen, Gothenburg (TOOsonix System ONE-M)
Active, not recruiting
- Cutaneous Neurofibroma
- TOOsonix System ONE-M
-
Copenhagen, Hovedstaden, Denmark
- +1 more
Jun 23, 2022
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Neurofibromatosis Type 1
-
Angers, France
- +3 more
Jan 12, 2023
Neurofibromatosis Type 1 Trial in Washington (CogmedRM, Mobymax)
Completed
- Neurofibromatosis Type 1
- CogmedRM
- Mobymax
-
Washington, District of ColumbiaChildren's National Health System
Mar 2, 2022